Intensity Therapeutics, Inc. (INTS)
NASDAQ: INTS · Real-Time Price · USD
7.42
-0.49 (-6.19%)
At close: Mar 12, 2026, 4:00 PM EDT
7.62
+0.20 (2.70%)
Pre-market: Mar 13, 2026, 8:14 AM EDT

Intensity Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Selling, General & Admin
4.796.093.532.422.161.17
Research & Development
7.2510.54.795.135.865.05
Total Operating Expenses
12.0416.598.327.558.016.22
Operating Income
-12.04-16.59-8.32-7.55-8.01-6.22
Interest Income
0.120.310.32000.07
Interest Expense
---0.31-0.08--
Other Non-Operating Income (Expense)
0.180-2.240.050.120.12
Total Non-Operating Income (Expense)
0.30.32-2.22-0.030.120.19
Pretax Income
-11.74-16.27-10.54-7.58-7.9-6.03
Net Income
-11.74-16.27-10.54-7.58-7.9-6.03
Net Income Attributable to Preferred Dividends
--1.32---
Net Income to Common
-11.74-16.27-10.54-7.58-7.9-6.03
Shares Outstanding (Basic)
110000
Shares Outstanding (Diluted)
110000
Shares Change (YoY)
66.36%61.40%152.67%-0.02%0.19%
EPS (Basic)
-15.75-29.25-34.50-55.50-58.00-44.00
EPS (Diluted)
-15.75-29.25-34.50-55.50-58.00-44.00
Free Cash Flow
-9.5-15.22-7.21-5.48-6.83-5.37
Free Cash Flow Per Share
-10.38-27.36-20.91-40.15-50.05-39.38
EBITDA
-12.01-16.56-8.17-7.37-7.84-6.11
EBIT
-12.04-16.59-8.32-7.55-8.01-6.22
Updated Nov 6, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q